Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis (FASST)
A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis
Sponsor: Inventiva Pharma
This PHASE2 trial investigates Diffuse Cutaneous Systemic Sclerosis and Scleroderma, Diffuse and is currently completed. Inventiva Pharma leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2019 — Apr 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Dec 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Inventiva Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ancona, Italy , Bad Nauheim, Germany , Barcelona, Spain , Berlin, Germany , Bialystok, Poland , Bordeaux, France , Brescia, Italy , Bydgoszcz, Poland , Cologne, Germany , Dresden, Germany and 31 more locations